The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 353, Issue 3, 1996, Pages 290-294

  Schlicker, Eberhard ^a   Marr, Iris ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

3H N( ) methylhistamine binding; Atypical neuroleptics; Clozapine; Clozapine N oxide; H3 receptors; N Desmethylclozapine; Olanzapine; Risperidone

Indexed keywords

ALPHA METHYLHISTAMINE; CLOZAPINE; CLOZAPINE N OXIDE; DESIPRAMINE; DRUG METABOLITE; HISTAMINE; HISTAMINE H3 RECEPTOR; N METHYLHISTAMINE; NEUROLEPTIC AGENT; NORADRENALIN; NORCLOZAPINE; OLANZAPINE; RADIOLIGAND; RAUWOLSCINE; REMOXIPRIDE; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; ZOTEPINE;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN HOMOGENATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; ELECTROSTIMULATION; LIGAND BINDING; MALE; NONHUMAN; NORADRENALIN RELEASE; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING, COMPETITIVE; CLOZAPINE; DIBENZOTHIEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE ANTAGONISTS; ISOTOPE LABELING; MALE; METHYLHISTAMINES; MICE; PIRENZEPINE; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3; REMOXIPRIDE; RISPERIDONE; STRUCTURE-ACTIVITY RELATIONSHIP; THIORIDAZINE; TRITIUM;

EID: 0029990288     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00168630     Document Type: Article

References (17)

1. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Houston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
3. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Handbook of experimental pharmacology, vol XXXIII. Springer, Berlin Heidelberg New York, pp 283-335
4. 3 receptor model. Naunyn-Schmiedeberg's Arch Pharmacol 348:498-503
5. 3 receptors. Psychopharmacology 116:464-468
6. 3-receptor: a target for developing new drugs. Prog Drug Res 39:127-165
7. 3-receptors. In: Schwartz JC, Haas HL (eds) The histamine receptor. Wiley-Liss, New York, pp 57-72
8. 1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiat 30:349-356
9. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14: 93-104
10. 3 receptor in rat brain. Br J Pharmacol 114:1523-1524
11. 3A receptor-mediated inhibition of noradrenaline release in the mouse brain cortex. Naunyn-Schmiedeberg's Arch Pharmacol 345:489-493
12. 2-adrenoceptors on noradrenergic terminals in mouse and rat brain cortex. Naunyn-Schmiedeberg's Arch Pharmacol 345:639-646
13. + ions, G protein and adenylate cyclase. Naunyn-Schmiedeberg's Arch Pharmacol 350:34-41
14. 3 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 352 [Suppl]:R24
15. Schwartz JC, Arrang JM, Garbarg M, Traiffort E (1995) Histamine. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 397-405
16. 4. Neuropsychopharmacology 7:261-284
17. 3-histamine receptor subtypes. Mol Pharmacol 38:610-613